business / news / / Endpoints News
Biopharma M&A is having one of its best stretches in years.
Biopharma M&A activity is currently experiencing one of its strongest periods in years.
KEY POINTS
- Big pharma companies are increasingly acquiring smaller biotech firms in recent deals.
- The definition of a 'big' deal in biopharma M&A has shifted compared to previous years.
- Cash returns to investors from these deals are impacting the startup biotech market.
COMPANIES
Summarized by Newsio from Endpoints News. How we summarize →